Squarepoint Ops LLC Sells 17,245 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Squarepoint Ops LLC decreased its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 59.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,864 shares of the company's stock after selling 17,245 shares during the quarter. Squarepoint Ops LLC's holdings in SpringWorks Therapeutics were worth $429,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of SpringWorks Therapeutics by 6.6% in the 4th quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock valued at $258,650,000 after acquiring an additional 445,593 shares during the last quarter. Boxer Capital Management LLC acquired a new position in SpringWorks Therapeutics during the fourth quarter valued at approximately $123,620,000. Pictet Asset Management Holding SA increased its stake in SpringWorks Therapeutics by 24.2% in the fourth quarter. Pictet Asset Management Holding SA now owns 2,391,412 shares of the company's stock valued at $86,402,000 after purchasing an additional 465,494 shares in the last quarter. Capital International Investors raised its holdings in SpringWorks Therapeutics by 92.7% in the fourth quarter. Capital International Investors now owns 2,361,746 shares of the company's stock worth $85,330,000 after purchasing an additional 1,136,079 shares during the period. Finally, ArrowMark Colorado Holdings LLC raised its holdings in SpringWorks Therapeutics by 0.5% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,499,134 shares of the company's stock worth $54,164,000 after purchasing an additional 7,072 shares during the period.

SpringWorks Therapeutics Price Performance

Shares of SpringWorks Therapeutics stock remained flat at $46.80 during trading on Friday. The stock had a trading volume of 3,119,418 shares, compared to its average volume of 2,282,253. The company has a market cap of $3.53 billion, a P/E ratio of -13.45 and a beta of 0.77. The business's 50 day simple moving average is $43.31 and its two-hundred day simple moving average is $43.46. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The firm had revenue of $49.09 million during the quarter, compared to analyst estimates of $64.19 million. On average, analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SWTX has been the subject of a number of recent analyst reports. Guggenheim restated a "neutral" rating and issued a $47.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday, May 12th. Evercore ISI downgraded SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Cowen lowered SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. Wedbush reiterated a "neutral" rating and set a $47.00 price objective (down previously from $81.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Finally, Barclays reissued an "equal weight" rating and set a $47.00 target price (down from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $52.57.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.